论文部分内容阅读
目的:评价索利那新用于治疗经尿道前列腺电切手术后膀胱痉挛患者的临床疗效。方法:选取2013年6月—2015年2月行经尿道前列腺电切手术患者77例,按照给药方式将其分为治疗组40例和对照组37例;治疗组患者术后当日口服索利那新治疗,对照组患者膀胱痉挛时给予吲哚美辛栓直肠栓剂,评价治疗后两组患者膀胱痉挛情况。结果:治疗组患者治疗72 h后膀胱痉挛的发生率为15.00%低于对照组为51.35%(P<0.01);治疗组患者术后24,48和72h膀胱痉挛次数、持续时间、24 h尿急次数及夜尿次数均少于对照组(P<0.05);治疗后无严重不良反应的发生。结论:索利那新用于治疗经尿道前列腺电切手术后膀胱痉挛患者疗效较为显著,同时也可预防术后膀胱痉挛的发生。
OBJECTIVE: To evaluate the clinical efficacy of solifenacin in the treatment of bladder spasm after transurethral resection of the prostate. Methods: Totally 77 patients undergoing transurethral resection of the prostate were selected from June 2013 to February 2015. They were divided into treatment group (n = 40) and control group (n = 37) according to the method of administration. The patients in the treatment group were given solina New treatment, control group patients with cystospasm indometacin suppository suppositories, evaluation of two groups of patients after treatment bladder spasm. Results: The incidence of bladder spasm in the treatment group was 15.00% at 72 h after treatment, which was 51.35% (P <0.01). The number of bladder spasm, the duration of 24 h and 24 h Emergency number and nocturnal urination were less than the control group (P <0.05); no serious adverse reactions after treatment. Conclusion: Solifenac is more effective in the treatment of bladder spasm after transurethral resection of prostate, and can also prevent postoperative bladder spasm.